Table 2.
Patients’ relative change in bone turnover marker levels at 120 days/LOCF versus baseline (ITT population).
| Change from baselinea | P1NP, n (%) | CTX, n (%) |
|---|---|---|
| PC | ||
| ↑ | 48 (16.1) | 45 (15.1) |
| ↓ | 235 (78.6) | 238 (79.6) |
| No change | 0 | 0 |
| BC | ||
| ↑ | 8 (8.2) | 3 (3.1) |
| ↓ | 81 (82.7) | 85 (86.7) |
| No change | 0 | 1 (1.0) |
BC, breast cancer; CTX, serum C-terminal cross-linking telopeptide of type I collagen; ITT, intent-to-treat; LOCF, last observation carried forward; PC, prostate cancer; P1NP, amino-terminal propeptide of type I collagen.
a
All values that were elevated relative to baseline were defined as an increase. All values that were reduced relative to baseline were defined as a decrease.